Journal article
Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Abstract
On June 17, 2024, the Food and Drug Administration approved 21-valent pneumococcal conjugate vaccine (PCV) (PCV21; CAPVAXIVE; Merck Sharp & Dohme, LLC) for adults aged ≥18 years. PCV21 does not contain certain serotypes that are included in other licensed pneumococcal vaccines but adds eight new serotypes. The Advisory Committee on Immunization Practices (ACIP) recommends use of a PCV for all adults aged ≥65 years, as well as adults aged 19-64 …
Authors
Kobayashi M; Leidner AJ; Gierke R; Farrar JL; Morgan RL; Campos-Outcalt D; Schechter R; Poehling KA; Long SS; Loehr J
Journal
MMWR Morbidity and Mortality Weekly Report, Vol. 73, No. 36, pp. 793–798
Publisher
Centers for Disease Control MMWR Office
DOI
10.15585/mmwr.mm7336a3
ISSN
0149-2195